Drug Trial Radar · NCT07321678
A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jan 22, 2026
Primary completion
Aug 10, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- Ascletis Pharma (China) Co., LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, placebo-controlled Phase II study is designed to evaluate the efficacy, safety, and tolerability of ASC30 oral tablets formulation in participants with Type 2 Diabetes Mellitus
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
ASC30 tabletsDrug
ASC30 tablets administered orally once daily
PlaceboDrug
Placebo administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in HbA1c up to 12 weeks in the treatment group compared with the placebo groupTime frame: Baseline and end of Week 12
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Ascletis Clinical Site
Riverside, California
Ascletis Clinical Site
San Jose, California
Ascletis Clinical Site
Denver, Colorado
Ascletis Clinical Site
Miami, Florida
Ascletis Clinical Site
Miami, Florida
Ascletis Clinical Site
Decatur, Georgia
Ascletis Clinical Site
Springfield, Missouri
Ascletis Clinical Site
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.